Humatrope And Human Enhancement: Lilly Drug Featured In Bioethics Report
Executive Summary
FDA's approval of Humatrope for idiopathic short stature plays a prominent role in a report by the President's Council on Bioethics as an example of the blurry line between medical need and human enhancement
You may also be interested in...
BIO Creates Policy Chief Position, Plans Reports Justifying Biotech Prices
The Biotechnology Industry Organization is continuing to expand its reach into the health policy arena with the creation of a "chief of policy" position
Lilly Humatrope Postmarket Plans: Voluntary Study, No Patient Registry
An assessment of the long-term safety and efficacy of Lilly's Humatrope for idiopathic short stature will rely on a voluntary ongoing postmarket research program
Lilly Humatrope Short Stature Prescribing Criteria Recommended By Cmte.
Lilly should develop prescribing criteria to guide the use of Humatrope for non-growth hormone deficient short stature in pediatric patients, members of FDA's Endocrinologic & Metabolic Drugs Advisory Committee suggested during a June 10 meeting